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Summary Using data of human immunodeﬁciency virus-positive patients with tuberculosis from three primary care
clinics in Kibera slums, Nairobi, Kenya, we report on the proportion that started antiretroviral treatment
(ART) and attrition (deaths, lost to follow-up and stopped treatment) before and while on ART. Of
427 ART eligible patients, enrolled between January 2004 and December 2008, 70% started ART, 19%
were lost to attrition and 11% had not initiated ART. Of those who started ART, 14% were lost to
attrition, making a cumulative pre-ART and ART attrition of 33%. ART uptake among patients with
TB was relatively good, but programme attrition was high and needs urgent addressing.
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Introduction
Human immunodeﬁciency virus (HIV)-positive patients
with tuberculosis (TB) in sub-Saharan Africa have high
death rates during and after TB treatment (Kelly et al.
1999; Harries et al. 2001; Mukadi et al. 2001). Antiret-
roviral treatment (ART) reduces mortality risk by 64–95%
and is now recommended for all HIV-positive patients with
TB (Lawn et al. 2006; WHO 2006; Tabarsi et al. 2009;
Velasco et al. 2009). Between 2006 and 2009, the preva-
lence of HIV among patients with TB in Kenya ranged
between 44% and 52% (MMWR 2001), and for such
patients, ART is vital for survival. There are three public
primary health care clinics in the informal settlement of
Kibera in Kenya, which are supported by the Non-
Governmental Organisation Medecins Sans Frontieres
(MSF). These three clinics offer integrated TB and HIV
services, and efforts have been made to offer ART to all
HIV-positive patients with TB.
Using routine programme data of newly registered adult
patients with TB who tested HIV positive and were
considered eligible for ART, we report on (i) the proportion
starting ART and (ii) attrition (deaths, lost to follow-up
and stopped treatment) before and while on ART.
Methods
Design
Study design and setting population
This was a retrospective cross-sectional study using routine
programme data conducted at three primary care clinics
belonging to the Ministry of Health in Kibera, an urban
slum setting in Nairobi with about 700 000 inhabitants.
The three clinics are supported by MSF and HIV, and TB
services are provided in the same health facility in an
integrated manner and by the same clinician. All newly
registered patients with TB presenting to the clinics
between January 2004 and December 2008 and found to
be HIV positive were included in the analysis.
ART for HIV-positive patients with TB
In Kenya, all HIV-positive patients with TB are eligible for
ART but the timing of ART initiation relative to starting
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CD4 counts <200 cells⁄mm
3 start ART as soon as they are
stabilized on TB treatment (usually between 2 and
8 weeks); patients with CD4 counts of 200–350 cells⁄mm
3
start ART on completion of the intensive phase of TB
treatment (after 8 weeks) and those with CD4 counts over
350 cells⁄mm
3 start ART after completing TB treatment.
Prior to starting ART, patients and guardians undergo
group and individual counselling. A home visit is made by
clinic staff before patients are started on ART. Patients
with TB were seen weekly for the ﬁrst 8 weeks of TB
treatment and monthly thereafter. CD4 measurements
coincided with TB clinic appointments.
The ﬁrst-line ART regimen for co-infected TB patients in
Kenya (NASCOP 2005) was a ﬁxed-dose combination of
stavudine (d4T), lamivudine (3TC) and efavirenz (EFV).
ART was offered free of charge in Kibera.
Data collection, outcomes and analysis
The source of data is TB and ART patient cards and
registers. Data were entered into an HIV⁄AIDS software
program (FUCHIA; Epicentre, Paris, France) daily using
standardized data collection sheets in the clinics.
Outcome data were for HIV-related variables including
ART uptake and attrition before and after starting ART.
On admission, height and weight were routinely measured
to determine the body mass index [BMI; weight in
kilograms (kg) divided by height in metre squared (m
2)].
A normal BMI was deﬁned as 18.5–24.9 kg⁄m
2. Malnu-
trition was deﬁned as a BMI <18.5 kg⁄m
2. Programme
outcomes were deﬁned as (i) alive and on follow-up (before
or after starting ART): patient who was alive and on
follow-up at the facility where he⁄she registered, (ii) lost to
follow-up: a patient who was never been seen back at the
ART facility for 6 months after the scheduled appointment
date, (iii) died: a patient who died for any reason, (iv)
stopped treatment: a patient who stopped ART for any
reason, (v) transferred out: a patient who was formally and
permanently transferred to another treatment facility. In
this analysis, ‘attrition’ was deﬁned as death, loss to
follow-up or stopped treatment (if on ART) and as death or
loss to follow-up (if not on ART). Patient outcomes were
censored on 31 December 2008. Data analysis was carried
out using stata 8.2 software (Stata corporation, College
Station, Texas 77845, USA).
Ethical approval
Ethics approval was received from the MSF and UNION
Ethics Review Boards. The projects functioned within the
framework of formal agreements with the Kenyan MOH.
The data in this study did not include patient identiﬁers
and constituted what was routinely collected as part of
programme evaluation.
Results
A total of 465 newly registered patients with TB were HIV
positive at their ﬁrst visit, of whom 38 (8%) had missing
outcome data and were excluded from the analysis. Of the
427 adults included, 56% were women, median age was
32 years (IQR, 28–38 years), 87% had pulmonary TB and
37% were malnourished. There were 6% who had never
been to school, 63% with a primary education, 29% with a
secondary education and 2% with a technical or university
qualiﬁcation.
Figure 1 shows follow-up outcomes for the 427 patients.
Of these, 48 were retained in care and were still waiting to
start ART at the time of data censoring, while 82 (19%)
were lost to attrition prior to starting ART; 297 (70%)
patients started ART, of whom 60 (14%) were lost to
attrition while on ART. A cumulative total of 142 (33%)
patients were lost to attrition either prior to or during
ART, from the time they were considered eligible. A
considerable proportion of attrition (58%) occurred prior
to ART. Loss to follow-up, deaths and stopping ART
constituted 73%, 25% and 2% of the total attrition,
respectively. Pre-ART attrition was stratiﬁed by CD4 range
(<200, 200–349 and >350 cells⁄mm
3, ranges that deter-
mine national guidelines on ART start time in relation to
TB treatment), but no signiﬁcant trend was observed. The
analysis was limited by the fact that among those patients
lost to attrition pre-ART, 43% had no record of a CD4
count most likely because it was never done.
Discussion
This study shows that, although about 7 of 10 HIV-
positive patients with TB start ART in integrated TB-HIV
clinics in Kibera, Kenya, more than 30% are lost to
attrition either before or during ART. Over half of this
attrition occurs in the pre-ART phase. Improving ART
uptake among HIV-positive patients with TB is a high
priority but a global challenge. By the end of 2007, only
100 000 (7.3%) of an estimated 1.37 million HIV-infected
patients with TB worldwide were reported to have started
ART (Harries et al. 2010). Thus, our study ﬁndings raise a
number of important issues.
First, the relatively high uptake (69%) of ART in Kibera
is very encouraging. However, attrition among patients
with TB prior to and after starting ART remains
unacceptably high. Second, nearly one in ﬁve patients
(constituting 58% of all attrition) was lost to attrition
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feeling better after starting TB treatment and deciding not
to return or postpone ART; possible unrecognized short-
comings in TB-HIV counselling; and CD4 turnaround
time and death. Recent changes in WHO guidelines
recommending that all HIV-positive patients with TB
receive ART irrespective of CD4 count (WHO 2009)
should help simplify the process of starting ART earlier,
by removing the CD4 hurdle. Finally, this analysis
highlights the need for programme reporting to include all
ART ‘eligible’ patients, rather than just those patients
started on ART, as ‘on ART’ analyses underestimate
attrition and present a distorted picture of programme
success.
Reducing attrition in co-infected TB patients would be
helped by simplifying the process of ART initiation by
implementing the new WHO guidelines (WHO 2009),
better emphasis on the importance of starting ART early
through more focused counselling and home visits prior to
starting ART and activating existing systems to actively
trace ART eligible patients (including those pre-ART) who
fail to return for follow-up. The latter two points are
currently being implemented and are likely to positively
inﬂuence ART uptake. Finally, routinely reporting pro-
grammatic attrition in both the pre-ART and ART phase to
better reﬂect overall attrition is needed.
The strengths of this study are that a relatively large
number of ART eligible patients with TB were studied,
outcomes were missing for only 8% of the cohort and, as
the data come from a programme setting, ﬁndings likely
reﬂect the operational reality on the ground. The limita-
tions are that being an observational study, there may have
been errors and omissions in recording, and patients
declared lost to follow-up may include unascertained
deaths. Although we do not have speciﬁc data to substan-
tiate this, during the time of the study, the government
of Kenya was relocating some of the population from
Kibera, which may have affected the attrition rate. This
aside, we do not know the exact reasons for attrition,
and this merits further qualitative studies.
In an informal slum setting in Nairobi, Kenya, ART
uptake among patients with TB is relatively good.
Started ART 
297 (70%) 
Retained and still waiting to 
start ART = 48 (11%) 
(Alive in the same facility = 29)
(Transfered out = 19) 
Preparation 
phase for ART  
ART phase  
Attrition = 82 (19%) 
(Lost to flow-up = 65) 
(Died = 17) 
TB patients 
eligible for ART 
n = 427 
Retained on ART by 
December 2008 
237 (56%) 
(Alive and on ART = 194)* 
(Transferred out = 43) 
Attrition = 60 (14%) 
(Lost to flow-up = 39) 
(Died = 18) 
(Stopped ART = 3)
Figure 1 Cumulative retention and attri-
tion among adult human immunodeﬁciency
virus-positive patients with tuberculosis
during the antiretroviral treatment (ART)
preparation phase and after starting ART
in Kibera, Kenya (2004–2008).
*In the same facility.
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forward for addressing this problem are urgently needed.
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